Page 18 - Pharmaceutical Firms

Lupin receives approval from the US FDA for its Selexipag for injection

In 2022, sales of the Selexipag Franchise in the US stood at $ 1.1 billion. The sales for January 1 to September 30, 2023, stood at $978 million

US sales momentum, margin gains to support pharma major Cipla's stock

Led by the US market which rose by 31 per cent, the company posted a 16 per cent growth in revenues

Pfizer Q2 results: Net profit declines 52% at Rs 149 cr, revenue slips 9.8%

Drug firm Pfizer Ltd on Saturday reported 52.11 per cent decline in net profit at Rs 148.96 crore for the second quarter ended September 2023. The company had logged a net profit of Rs 311.07 crore in July-September period a year ago, according to a regulatory filing by Pfizer. Revenue from operations declined 9.76 per cent to Rs 575.21 crore in the quarter as against Rs 637.47 crore in the year-ago period. Total expense was at Rs 410.76 crore, down 5.66 per cent. Total income was at Rs 611.28 crore in September quarter 2023-24, down 7.62 per cent.

Piramal Pharma clocks 11% revenue growth in quarter ending September

Company's Ebitda grows 44% year-on-year, Chairperson Nandini Piramal anticipates a stronger financial performance in H2

ED raids pharma firm Parabolic Drugs, promoters in money laundering probe

The Enforcement Directorate on Friday carried out raids at multiple premises of Chandigarh-based pharmaceutical company Parabolic Drugs and its promoters as part of a money laundering investigation linked to an alleged bank loan fraud case, official sources said. The searches by the central agency covered a total of 17 premises in Delhi, Mumbai, Chandigarh and Panchkula and Ambala in Haryana, they said. The action is being undertaken under the provisions of the Prevention of Money Laundering Act (PMLA) and the ED case stems from a 2021 CBI FIR against the company and its promoters Vineet Gupta and Pranav Gupta among others, the sources said. The agency, as per the sources, is also looking at some documents from Sonepat-based Ashoka University as two directors of the company, Vineet Gupta and Pranav Gupta, have been associated with the educational institution in the past. The two had stepped down from all the boards and committees of the university in 2022, days after the CBI ...

Fewer generics enter market after linagliptin's patent expiry this August

When Sitagliptin went off patent, nearly 200 brands were vying for a share of the market

2,350 acres set aside for pharma and medical parks in Uttar Pradesh

Chief Minister Yogi Adityanath has envisioned increasing the state's contribution to the pharma industry from 2 per cent to 10-12 per cent

Sun Pharma recalls 144 bottles of anti-depression drug from US market

Sun Pharmaceutical Industries Inc has recalled 144 bottles of a generic anti-depression medicine from the US market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA). The US-based subsdiary of the Mumbai-headquartered drug company initiated the recall for the affected lot of Bupropion Hydrochloride extended-release tablets due to "failed dissolution specifications,", the US health regulator said in its latest Enforcement Report. The affected lot was manufactured at Sun Pharma's Halol-based plant in Gujarat and was distributed in the US by Sun Pharmaceutical Industries Inc, based in Princeton, New Jersy, it said. Bupropion is a medication commonly used to treat depression. The US-based drug maker initiated the voluntary Class III nationwide (US) recall on October 4 this year. As per the US FDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health ...

Glenmark Pharma launches triple-combination drug for Type 2 Diabetes

Medication will be sold under the brand name Zita DM, will be priced at Rs 14 per tablet

PLI scheme effect? Bulk drug imports from China slow, shows data

Experts say scheme to boost local manufacturing will take 5-7 years to show tangible results

Glenmark gets USFDA nod to market generic version of Otezla tablets

Glenmark's current portfolio includes a total of 188 products that have been authorised for distribution in the US marketplace

Zydus Lifesciences appoints Punit Patel as president & CEO of Americas

Punit Patel will oversee the business operations of all Zydus entities in North America, including generics, injectables, specialty business, rare and orphan disease portfolio

Pharma result preview: US stable, India muted in the second quarter

Hospital occupancy rates rise 200-400 bps, while diagnostic sector sees seasonal benefits

FDA has accepted NDA for dermatological drug Deuruxolitinib: Sun Pharma

Sun Pharmaceutical Industries Ltd said that it had submitted an 8mg twice-daily regimen of deuruxolitinib for FDA review

Apotex seeks $118 million from Panacea for collaboration pact breach

Canada-based Apotex Inc has sought USD 118.14 million from Panacea Biotec over breach of a collaboration agreement inked in 2014, the capital-based drug firm said on Thursday. The company has received a notification dated October 4 from the International Court of Arbitration, Paris, intimating that an arbitration proceeding has been initiated as per a request by Apotex Inc, Panacea Biotec said in a regulatory filing. Apotex has alleged that the company has breached its obligations under the collaboration agreement for research, development, licence, supply and sale of products inked on May 9, 2014, it added. Apotex has alleged that there has been a purported delay in seeking approval from US Food and Drug Administration for the product mentioned in the said agreement, Panacea Biotec said. "Apotex has claimed USD 118.14 million towards outsized alleged losses plus interest thereon to the extent permissible under the applicable law," it added. The company believes it is not in breac

Stride Pharma Global receives USFDA approval or Efavirenz, other drugs

The company aims to launch about 60 new products in the next three years in the US market

Schedule M likely to be revised to bring it closer to WHO standards

The draft rules, still under consideration, include provisions to strengthen quality control and the safety of drugs manufactured in India

Medicine to manufacturing: Nano is the next frontier in 3D printing

Nano-level 3D printing can have various uses in medicine, like growing tissue cells to regenerate organs. Nano robots in bodies can attack cancer cells

Suven Pharma gets a new board as Advent International completes stake buy

Advent had announced the acquisition of a significant stake in Suven Pharma in December of the previous year from the Jasti family

Glenmark, Cosmo partner to bring acne treatment Winlevi to Europe, S Africa

This agreement grants Glenmark the exclusive right to commercialise Winlevi in 15 EU countries, South Africa, and the UK